Roland Newman, Ph.D. joined Tanabe Research Laboratories as Chief Scientific Officer in 2010, bringing more than three decades of experience in immunology, molecular biology and biochemical research. Dr. Newman previously served as Principal at RANA Consulting, a biotechnology consulting company with special emphasis on Japanese-U.S. pharmaceutical partnering. Prior to that, he was Senior Director of Business Development at Biogen-Idec, having been head of the Molecular Immunology Department at Idec Pharmaceuticals. During his time at Idec, he was co-inventor of Rituxan® and Zevalin® and co-developed several other therapeutic antibodies for oncology and autoimmune diseases. Dr. Newman has more than 100 peer-reviewed publications, several book chapters and more than 30 patents. Prior to his industrial experience, Dr. Newman was Assistant Professor at the University of California San Diego and a visiting scientist at the Salk Institute in San Diego. He obtained his Ph.D. at the University of Bath in England and completed post-doctoral research at the Imperial Cancer Research Fund laboratories in London and the University Medical Clinic in Cologne, Germany.